Michael Jacobson, MD
Ophthalmology · Atlanta, GANPI 1376546549
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $28,868 of the $40,211 with a category attached, or 71.8%. US Retina LLC accounts for 71.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $14,414 and has fallen 98.7% since, to $193 in 2025. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $156.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$29K
- Alimera Sciences, Inc.$3K
- Genentech USA, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$1K
- AbbVie$1K
- Apellis Pharmaceuticals, Inc.$732
- plus $4K from 14 others
Across 3 payments — averaging $3496.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$10K
What the payments were for
- Speaking & faculty fees$1,8655%
- Food & beverage$9,47824%
- Ownership interest$28,86872%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $28,868 |
| Alimera Sciences, Inc. | 33 | $2,526 |
| Genentech USA, Inc. | 47 | $1,613 |
| Regeneron Healthcare Solutions, Inc. | 46 | $1,451 |
| AbbVie(2 entities) | 54 | $1,265 |
| Apellis Pharmaceuticals, Inc. | 11 | $732 |
| Notal Vision, Inc. | 2 | $665 |
| Astellas Pharma US Inc | 12 | $661 |
| Novartis | 16 | $607 |
| Alcon | 4 | $515 |
| Carl Zeiss Meditec USA, Inc. | 3 | $381 |
| Bausch & Lomb Americas Inc. | 3 | $312 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $136 |
| Dutch Ophthalmic, USA | 1 | $127 |
| Regeneron | 1 | $123 |
| Eyepoint US, Inc. | 4 | $79 |
| Coherus Oncology, Inc. | 3 | $64 |
| Kala Pharmaceuticals, Inc. | 2 | $42 |
| Halozyme Inc | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$1,830
- VABYSMO$626
- NGENUITY$515
- Syfovre$508
- EYLEA$361
- XIPERE$288
- OZURDEX$273
- VISUDYNE$145
- Clarus 700$133
- Lucentis$128
- CLARUS$128
- EVA Ophthalmic Surgical System$127
- CIRRUS HD-OCT$120
- EYLEA HD$111
- Izervay$105
How this compares
$40,211 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 26 | $9,007 |
| Prednisolone Acetate | 84 | $4,851 |
| Bromfenac Sodium | 11 | $2,736 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $2,259 |
| Atropine Sulfate | 50 | $2,096 |
| Ketorolac Tromethamine | 24 | $974 |
| Acetazolamide | 33 | $444 |
| Ciprofloxacin Hcl | 28 | $355 |
| Latanoprost | 16 | $184 |
| Timolol Maleate | 13 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $136 | $9,00726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Gagan SawhneyAtlanta$582K
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.